Japan’s Takeda is acquiring Nimbus Therapeutics subsidiary Nimbus Lakshmi and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858 in a deal worth up to $6 billion.
Source: Drug Industry Daily